Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 12

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 12
---
,829 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 EBITDA Adjusted LTM EBITDA Adj ( in million EUR ) Net Revenue 6,591 6,655 6,811 7,007 7,212 7,373 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 LTM revenue ( in million EUR ) 1,239 1,375 1,450 1,519 1,631 1,702 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 EBITDA Reported LTM EBITDA ( in million EUR ) Margin (%) Margin (%) 18.8% 20.7% 21.3% 21.7% 22.6% 23.1% 22.2% 22.7% 23.6% 24.2% 24.7% 24.8%

- 14 - Q1 2025 Results Strong Momentum Helping to Significantly Outpace Anticipated IRA Impact Business Performance Financials Final Remarks Annex EBITDA Adjusted (in million EUR except for EBITDA Adj margin and growth) Strong EBITDA momentum across the board L ed by Biopharma : Volume growth CPL reduction Yield improvement Operational leverage and cost discipline Anticipated IRA impact Note: All figures are presented on a consolidated basis (including Biotest). 1 2 3 4 5 6 7 8 350 428 400 - 28 +22.2% +14.3% EBITDA Adj. Q1 2024 Biopharma EBITDA Adj. Q1 2025 Diagnostic Bio Supply & Others Opex EBITDA Adj. Q1 2025 LFL IRA 21.6% 23.4% 22.4% EBITDA Adj MG Growth

- 15 - Q1 2025 Results Q1’25 Var vs PY Q1’24 50 400 350 EBITDA Adjusted 69 (61) (130) Inventories 61 (93) (154) Receivables 81 26 (55) Payables 211 (128) (339) Net working capital (67) (128) (61) CAPEX (17) (39